In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e15159-e15159
Abstract:
e15159 Background: Carcinoma of the advanced cervical esophagus is a highly virulent disease. Although surgery is considered the standard therapy, the results of surgery alone remain poor. The present study analyzes the efficacy of concurrent chemoradiotherapy (CCRT) with S-1 and cisplatin for advanced cervical esophageal carcinoma (ACEC). Methods: CCRT comprised two courses, 30-Gy radiotherapy over 3 weeks (2 Gy per fraction, 5 times a week) accompanied by daily oral S-1 powder (80 mg/m 2 /day) for 2 weeks and a 24-hr cisplatin infusion (70 mg/m 2 ) on Day 8. An identical course was administered after a 2-week break. Responders received a 5-week cycle of chemotherapy with S-1 and cisplatin. Results: Twenty-one subjects, 3 with Stage II, 14 with Stage III, and 4 with Stage IV ACEC participated, and all completed the CCRT courses. Eighteen subjects received a total of 59 cycles of chemotherapy after CCRT and a median of 3 cycles per subject was administered (range: 1 to 9 cycles). Complete response rates in subjects with Stage II, Stage III, and Stage IV diseases were 100%, 85.7%, and 25%, respectively, and a dysphagia-free status was found in 80.9%. The most serious toxicity was myelosuppression; Grades 3 and 4 neutropenia occurred in 33.3% and 9.5%, of subjects, respectively. Non-hematologic toxicities were moderate. The most common were Grade 2 nausea (38.0%), esophageal pain, and oral mucositis (19.0% each) and renal dysfunction (9.5%). Adverse events from the first course of CCRT resolved during the 2-week treatment break. Overall median progression-free survival was 1.5 years and the median survival time was 2.5 years. The 1- and 5-year survival rates were 75.0 and 27.7%, respectively. Conclusions: This regimen showed favorable antitumor activity, improving survival and quality of life with tolerable toxicity, and could become an alternative to conventional surgery for the treatment of ACEC.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2013.31.15_suppl.e15159
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2013
detail.hit.zdb_id:
2005181-5
Permalink